Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 7/20 | 0.56 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453755 | 1.00 | CYP46A1 (0.56) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL29453706 | 0.93 | CYP46A1 (0.56) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL22719375 | 0.93 | CYP46A1 (0.56) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL22719126 | 0.92 | CYP46A1 (0.54) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL29453690 | 0.92 | CYP46A1 (0.54) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL22719482 | 0.91 | CYP46A1 (0.58) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL29453697 | 0.91 | CYP46A1 (0.58) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL29453730 | 0.90 | CYP46A1 (0.53) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL22719220 | 0.90 | CYP46A1 (0.53) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 | |
| SCHEMBL24710216 | 0.90 | CYP46A1 (0.53) | CYP46A1HTR2AHTR2CKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261510-A1 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SAGE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2020243027-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYP46A1, CYP26A1, CYP21A2 | CYP46A1 1/4885HTR2A 1095/4885HTR2C 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.